Abstract:The upregulation of chemokine genes and the subsequent T-lymphocyte recruitment to the graft are early events in the development of acute cardiac transplant rejection or cardiac allograft vasculopathy. In the present study, a combined immunosuppressive regimen of C-X-C motif chemokine 9 (CXCL9) antibody (Ab), CXCL10 Ab and FTY720 was used in order to reduce the infiltration of memory T lymphocytes and prolong graft survival in a retransplantation murine model. BALB/c donor hearts were transplanted heterotopically into C57BL/6 mice at day 28 after skin transplantation. The mice were divided into four groups: i) Control (normal saline), ii) CXCL9 Ab and CXCL10 Ab [150 μg; once daily (qd); intraperitoneal (ip)], iii) FTY720 (0.2 mg/day; qd; ip) and iv) combined (2 mg/kg/day; qd; ip). Measurements of the median survival time of the cardiac grafts, histological examination, reverse transcription-quantitative polymerase chain reaction analysis, enzyme-linked immunosorbent assay and a mixed lymphocyte reaction were performed. The median graft survival time of the combined group was prolonged (9.3 days) compared with that of the control group (3.5 days) (P<0.001). Histological examination revealed that the combined treatment group graft rejection pathological score was 0.50, while the control group score was 3.62 (P<0.001). In addition, the gene expression level of interleukin (IL)-2 was significantly lower and the levels of IL-10 and transforming growth factor-β (TGF-β) were significantly higher in the combined group compared with those in the control group (P<0.001). Furthermore, the serum concentration levels of IL-2 and interferon-γ (IFN-γ) were significantly lower (P<0.001) and the concentration of IL-10 was significantly higher (P<0.05) in the combined group compared with those in the control group. In the mixed lymphocyte reaction, T-cell proliferation was found to be significantly lower in the combined treatment group than that in the control group (P<0.001). In conclusion, treatment with CXCL9 Ab and CXCL10 Ab or FTY720 reduced the graft infiltration of inflammatory cells, inhibited T-cell proliferation and prolonged graft survival. The combined treatment regimen of CXCL9 Ab, CXCL10 Ab and FTY720 was found to significantly reduce the infiltration of inflammatory cells in the graft and prolong graft survival.

Electrospun Polymer Fibers Modified with FK506 for the Long-Term Treatment of Acute Cardiac Allograft Rejection in a Heart Transplantation Model.

Delivery of FK506-loaded PLGA Nanoparticles Prolongs Cardiac Allograft Survival.

Improving Acute Cardiac Transplantation Rejection Therapy Using Ultrasound-Targeted FK506-loaded Microbubbles in Rats.

Bioinspired Β-Glucan Microcapsules Deliver FK506 to Lymph Nodes for Treatment of Cardiac Allograft Acute Rejection

Immunosuppressive effect of PLGA-FK506-NPs in treatment of acute cardiac rejection via topical subcutaneous injection

Poly(Lactic-Co-Glycolic Acid) (PLGA) Nanoparticles Loaded with FK506 Inhibits Acute Heart Transplantation Rejection via Regulation of Monocyte Dendritic Cells Receptor

Combination of C-X-C motif chemokine 9 and C-X-C motif chemokine 10 antibodies with FTY720 prolongs the survival of cardiac retransplantation allografts in a mouse model

FK506-loaded PLGA nanoparticles improve long-term survival of a vascularized composite allograft in a murine model

Effect of Switch from Cyclosporine to FK506 on Renal Graft Outcome in Patients after Initial Acute Rejection

CLINICAL USE OF FK506 AS PRIMARY ANTI-REJECTION AGENT IN RENAL ALLOGRAFT RECIPEINTS

Short-term Pharmacological Inhibition of MyD88 Homodimerization by a Novel Inhibitor Promotes Robust Allograft Tolerance in Mouse Cardiac and Skin Transplantation.

A Pilot Clinical Study of Tacrolimus(fk506) in Cadavaric Renal Transplant Recipients with Delayed Graft Function and Early Acute Rejection

Clinical Study on the Use of FK506 after Renal Transplantation

The Prospective Randomized Study on Prevention of Cadaveric Renal Allograft Rejection by Tacrolimus (FK506)

Preparation and evaluation of novel oral tacrolimus nanocochleates for organ transplantation to reduce individual differences and improve drug safety

Clinical Application of FK506 in Renal Transplantation

Pharmacokinetic and Clinical Study of FK506

FK506 treatment in a Long-term chronic rejection rat model of small bowel transplantation.

Reversal of accelerated renal allograft rejection with FK 506

Prevention of Acute and Chronic Rejection of Rat Heart Allografts by Oral Administration of Tolerogenic Donor Recipient Allochimeric Class I Mhc Proteins

Long-term Evaluation of FK506 Based Immunosuppressive Therapy in Kidney Transplantation